Stempoint Capital LP
StemPoint Capital LP is a hedge fund headquartered in New York, NY, founded in 2023 by Michelle Ross and Sean Tan. The firm specializes in the global life sciences sector, particularly biopharma and biotechnology, and employs a research-driven approach to equity investing. As of 2025, it serves institutional and high-net-worth clients, with approximately 6 employees.
Investment Strategy
StemPoint Capital pursues a long-biased, biopharma-focused long/short equity strategy, investing across large-cap pharmaceuticals and small/mid-cap biotechnology firms. The fund employs a fundamental, science-driven research process to identify sector trends and disease indications, aiming to capture both growth and defensive attributes for absolute returns through varying market cycles. Sector exposure is diversified across the life sciences, with top holdings frequently in innovative biotech and pharma companies.
Top Holdings
Equity Positions (50)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
S SNDX | SYNDAX PHARMACEUTICALS INC | 7.13% | $22.2M | 2,372,634 | $15.19 | $9.37 | +$2.6M |
I IMVT | IMMUNOVANT INC | 6.68% | $20.8M | 1,300,860 | $25.15 | $16.00 | +$6.2M |
S SRRK | SCHOLAR ROCK HLDG CORP | 6.00% | $18.7M | 528,115 | $35.40 | $35.42 | +$502.1K |
C CNTA | CENTESSA PHARMACEUTICALS PLC | 5.34% | $16.6M | 1,265,672 | $14.79 | $13.14 | +$8.1M |
M MDGL | MADRIGAL PHARMACEUTICALS INC | 5.12% | $15.9M | 52,694 | $324.85 | $302.64 | +$2.4M |
Options Positions (3)
| Ticker | Security | Action | Type | Notional Value | Contracts | Underlying Price | Premium Paid | Change (Contracts) | Change (Value) |
|---|---|---|---|---|---|---|---|---|---|
R ROIV | ROIVANT SCIENCES LTD | New | Call | $617.6K | 9,150 | $11.27 | $11.27 | +9,150 | +$617.6K |
I IMVT | IMMUNOVANT INC | New | Call | $310.0K | 1,000 | $16.00 | $16.00 | +1,000 | +$310.0K |
G GERN | GERON CORP | New | Call | $52.5K | 3,000 | $1.41 | $1.41 | +3,000 | +$52.5K |